Alicia Eby, MD
Ophthalmology · Traverse City, MINPI 1265851083
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,134 of the $9,154 with a category attached, or 67.0%. It is spread thinly across 25 manufacturers, the largest accounting for just 21.5%. Among ophthalmology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 219 payments — averaging $41.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$2K
- Rxsight Inc$2K
- AbbVie$972
- Alcon$966
- Biotissue Holdings Inc.$722
- Johnson & Johnson Surgical Vision, Inc.$629
- plus $2K from 19 others
Across 9 payments — averaging $2972.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$27K
What the payments were for
- Consulting fees$1,50016%
- Food & beverage$6,13467%
- Education$1,50016%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 17 | $1,967 |
| Rxsight Inc | 10 | $1,736 |
| AbbVie(2 entities) | 40 | $972 |
| Alcon | 29 | $966 |
| Biotissue Holdings Inc. | 14 | $722 |
| Johnson & Johnson Surgical Vision, Inc. | 14 | $629 |
| Genentech USA, Inc. | 14 | $311 |
| Bausch & Lomb Americas Inc. | 11 | $296 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $200 |
| Amgen(2 entities) | 10 | $193 |
| Astellas Pharma US Inc | 3 | $155 |
| Aerie Pharmaceuticals, Inc. | 6 | $151 |
| Novartis | 8 | $136 |
| Sight Sciences, Inc. | 7 | $114 |
| Regeneron Healthcare Solutions, Inc. | 5 | $114 |
| Kala Pharmaceuticals, Inc. | 5 | $110 |
| Dompe US, Inc. | 5 | $102 |
| Oyster Point Pharma, Inc. | 4 | $88 |
| NEW World Medical,inc. | 3 | $58 |
| Harrow Eye, LLC | 1 | $39 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $25 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $18 |
| Glaukos Corporation | 1 | $18 |
| Shire North American Group Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$1,500
- RXSIGHT INJECTOR CARTRIDGE$1,500
- RXSIGHT INJECTOR HANDPIECE$1,500
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$1,500
- LIGHT ADJUSTABLE LENS (LAL)$1,500
- CATALYS SYSTEM$225
- Tecnis IOL$214
- Clareon$131
- LUMIGAN$125
- COMBIGAN$125
- AcrySof IQ PanOptix UV IOL$118
- MIEBO$113
- XIIDRA$113
- LenSx$113
- XDEMVY$101
How this compares
$9,154 in reported general payments places this provider in the 90th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 100 | $121,589 |
| LumiganBimatoprost | 88 | $41,209 |
| Bromfenac Sodium | 120 | $31,178 |
| Restasis MultidoseCyclosporine | 16 | $13,641 |
| ProlensaBromfenac Sodium | 38 | $12,926 |
| Loteprednol Etabonate | 82 | $12,400 |
| Cyclosporine | 16 | $8,189 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 34 | $8,088 |
| Latanoprost | 342 | $6,799 |
| TafluprostTafluprost/Pf | 16 | $5,263 |
| Travoprost | 28 | $4,898 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $4,507 |
| Prednisolone Acetate | 71 | $3,594 |
| Timolol Maleate | 65 | $3,148 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 13 | $2,936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Restasis Multidose | $972 | $176,439204 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $200 | $25,326120 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $151 | $4,50712 claims |
| AlconSimbrinza | $966 | $2,93613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 674 ophthalmology providers in Michigan.
Other ophthalmology in Traverse City
- Justin TannirTraverse City$21K
- Manjool ShahAnn Arbor$609K
- Gregory KatzYpsilanti$401K
- Timothy PageBirmingham$250K
- David ZacksAnn Arbor$177K
- Scott WesthouseGrand Rapids$138K
- Bret HughesDetroit$123K
- Pradeepa YoganathanDetroit$115K
- Jason MillerAnn Arbor$104K
- David TukelDearborn$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.